Shamburg News · 8-K filed Nov 12, 2026, 8:01 AM EST

Kyverna Completes Miv-cel BLA Submission for SPS and Reports Q3 2026 Financial Results

KYTX · Kyverna Therapeutics, Inc.

  • Earnings
  • Other event
  • Materiality: high

Kyverna Therapeutics reported a business update and third quarter 2026 financial results for the quarter ended September 30, 2026, in a press release furnished as Exhibit 99.1. The company stated it completed its rolling BLA submission for miv-cel in stiff person syndrome, seeking priority review, and elected to deprioritize its KYV-102 program. For the quarter it reported R&D expenses of $27.0 million, G&A expenses of $15.9 million, a net loss of $41.9 million, or $0.68 per share, and $170.6 million in cash, equivalents, and marketable securities.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001193125-26-457040.

Written from the filing by Shamburg Markets. Figures are as reported by the company.